Medical device maker Insulet convinced a jury that Korean rival EOFlow owes it $452 million in damages for stealing trade ...

Medical device maker Insulet convinced a jury that Korean rival EOFlow owes it $452 million in damages for stealing trade ...

The Massachusetts district court awarded Insulet a total of $452 million, including $170 million in compensation plus $282 ...

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its ...

Insulin pump maker Insulet won $452 million in its trade secret case against Korean rival EOFlow, the company announced on ...

The lawsuit revolved around Insulet's Omnipod tubeless insulin pump – used with continuous glucose monitors (CGMs) to create ...

A jury found that competitor EOFlow and former executives misappropriated trade secrets for Insulet’s Omnipod insulin pumps.

Oflow executives reportedly sell shares before stock hits lower limit Insider trading allegations emerge as Oflows stock ...

Insulet的最新发展包括首次突破20亿美元的全年收入，Omnipod总收入增长26%，以及FDA批准Omnipod 5用于2型糖尿病。公司正在扩大销售团队以瞄准这一新的市场细分，预计到2025年将占据40%以上的胰岛素密集型市场。对于第四季度，Insulet预计Omnipod总收入增长将在13%至16%之间，公司总增长将在12%至15%之间。

A federal jury awarded Insulet Corp. $452 million against Eoflow Co. Ltd., concluding that Eoflow and other defendants stole ...

Insulet (Nasdaq:PODD) announced that it successfully defended its intellectual property against EOFlow in U.S. federal court.

A trial team at Goodwin Procter won a $452 million verdict for client Insulet Corp. in a trade secrets case involving insulin ...